Evidence map›Paper›PMID 26135632›Full record

ArticleMolecular medicine reports2015

Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease.

Youn-Jeong Shin, Yeo Jin Jeon, Namhee Jung, Joo-Won Park, Hae-Young Park, Sung-Chul Jung

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Tubular FoxP2 and Kidney Fibrosis.Journal of the American Society of Nephrology : JASN · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. α-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Youn-Jeong ShinDepartment of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158‑710, Republic of Korea.
Yeo Jin JeonDepartment of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158‑710, Republic of Korea.
Namhee JungDepartment of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158‑710, Republic of Korea.
Joo-Won ParkDepartment of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158‑710, Republic of Korea.
Hae-Young ParkDepartment of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158‑710, Republic of Korea.
Sung-Chul JungDepartment of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158‑710, Republic of Korea.
Ewha Womans University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding the α-galactosidase A (α-Gal A) lysosomal enzyme, which results in globotriaosylceramide (Gb3) storage in vascular endothelial cells and different cell types throughout the body. Involvement of the kidney and heart is life threatening, and fibrosis of these organs is considered to be involved in the pathogenesis of Fabry disease. An increased concentration of deacylated Gb3 (lyso‑Gb3) in the plasma of symptomatic patients has also been suggested as a causative molecular event. To elucidate the molecular mechanisms involved in renal fibrosis in Fabry disease, the present analyzed the changes in global gene expression prior to and following Gb3 or lyso‑Gb3 treatment in two types of kidney cell lines, human proximal renal tubular epithelial (HK‑2) and mouse renal glomerular mesangial (SV40 MES 13) cells. Gb3 and lyso‑Gb3 treatment regulated the expression of 199 and 328 genes in each cell type, demonstrating a >2.0‑fold change. The majority of the biological functions of the regulated genes were associated with fibrogenesis or epithelial‑mesenchymal transition (EMT). The gene expression patterns of sphingolipid‑treated HK‑2 cells were distinguishable from the patterns in the SV40 MES 13 cells. Several genes associated with the EMT were selected and evaluated further in kidney cells and in Fabry mouse kidney tissues. In the SV40 MES 13 cells, the DLL1, F8, and HOXA11 genes were downregulated, and FOXP2 was upregulated by treatment with Gb3 or lyso‑Gb3. In the HK‑2 cells, the ADAMTS6, BEST1, IL4, and MYH11 genes were upregulated. Upregulation of the FOXP2, COL15A1, IL4, and MYH11 genes was also observed in the Fabry mouse kidney tissues. The gene expression profiles in kidney cells following the addition of Gb3 or lyso‑Gb3 revealed substrate‑specific and cell‑specific patterns. These findings suggested that Gb3 and lyso‑Gb3 lead to renal fibrosis in Fabry disease through different biochemical modulations.

Indexed as

Gene Expression RegulationADAM ProteinsADAMTS ProteinsAnimalsBestrophinsCalcium-Binding ProteinsCell Line, TransformedChloride ChannelsDisease Models, AnimalEpithelial CellsEpithelial-Mesenchymal TransitionEye ProteinsFabry DiseaseGene Expression ProfilingGlycolipidsHomeodomain ProteinsADAM ProteinsAdamts6 protein, humanADAMTS ProteinsBEST1 protein, humanBestrophinsCalcium-Binding ProteinsChloride ChannelsDlk1 protein, mouseEye Proteinsglobotriaosylceramideglobotriaosyl lysosphingolipidGlycolipidsHomeodomain ProteinsHoxa11 protein, mouseIntercellular Signaling Peptides and ProteinsSphingolipidsTrihexosylceramides

Identifiers

PMID26135632
PMCPMC4581816
OpenAlexW2119382610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.